Synopsis:
JFL Life Sciences shares rose after receiving a ₹29.99 crore order from JD Healthcare for Merilyzer Quantilyte Machines.
This Penny Pharma Stock, engaged in manufacturing and marketing pharmaceutical products, including beta-lactam dry powder injections, tablets, capsules, and oral rehydration solutions for domestic and international markets, hit a 5 percent upper circuit after receving an order worth Rs. 30 cr from JD Healthcare.
With a market capitalization of Rs. 43.22 crores, the shares of JFL Life Sciences Limited hit a 5 percent upper circuit of Rs. 13.10 per share on Monday, up from its previous closing price of Rs. 12.50 per share.
Reason Behind the Surge
JFL Life Sciences Limited has received a new order from JD Healthcare. The order involves supplying Merilyzer Quantilyte Machines, which are pharmaceutical and healthcare instruments. This contract is valued at around Rs. 29.99 crore and is to be completed within 180 days.
This order is expected to significantly boost the company’s revenue and strengthen its position in the pharmaceutical and healthcare equipment segment. It will enhance the company’s market presence, support business growth, and build stronger relationships with domestic healthcare clients.
Company Overview
JFL Life Sciences Limited was incorporated in April 2010 by Mr. Smiral Ashwinkumar Patel. The company is a pharmaceutical manufacturing company and operates primarily out of its facilities in Bavla, near Ahmedabad, and is recognized for its WHO-GMP certification, ensuring compliance with stringent quality and international manufacturing standards.
The company focuses on the manufacture and marketing of a broad portfolio of pharmaceutical products, including Beta-Lactam dry powder injectables as well as solid oral dosage forms like tablets and capsules.
JFL Life Sciences Limited has carved out a niche as a specialist in Beta-Lactam and general pharmaceutical formulations, serving both domestic and international markets. Its robust product range and established manufacturing infrastructure allow it to cater to diverse client needs, including large-scale production and private label manufacturing.
Recent quarter results
Coming into financial highlights, JFL Life Sciences Limited’s revenue has increased from Rs. 9.54 crore in Q1 FY25 to Rs. 11.59 crore in Q1 FY26, which has grown by 21.49 percent. The net profit has decreased by 60.73 percent from Rs. 1.91 crore in Q1 FY25 to Rs. 0.75 crore in Q1 FY26. JFL Life Sciences Limited’s revenue and net profit have grown at a CAGR of 22.15 percent and 63.14 percent, respectively, over the last five years.
In terms of return ratios, the company’s ROCE and ROE stand at 15.8 percent and 11.1 percent, respectively. JFL Life Sciences Limited has an earnings per share (EPS) of Rs. 1.26, and its debt-to-equity ratio is 0.27x.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma stock hits 5% upper circuit after receiving order worth ₹30 Cr from JD Healthcare appeared first on Trade Brains.